MHRA Approves Remibrutinib for Chronic Spontaneous Urticaria
The MHRA has approved remibrutinib for the treatment of adults with chronic spontaneous urticaria.
Asset / Drug
Drug and asset intelligence for remibrutinib with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
A Phase 3 study is assessing the efficacy, safety, and tolerability of remibrutinib in patients with moderate to severe hidradenitis suppurativa.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.